NCT06348888
A Study to Learn About How Itraconazole and Carbamazepine Affect the Level of BAY2927088 in the Blood When These Drugs Are Taken Together by Healthy Participants other 1 completed NCT03486496
Gefitinib and Berberine in the First-line Treatment of Lung Adenocarcinoma With EGFR Mutation treatment 2 unknown_status NCT02140333
Erlotinib 100mg or 150mg in Treating EGFR Mutated NSCLC treatment 3 unknown_status NCT06360211
A Study to Learn About How BAY2927088 Affects the Level of Midazolam in the Blood When Both Drugs Are Taken Together in Healthy Participants other 1 completed NCT06221475
A Study to Learn How BAY2927088 is Taken up and Handled by the Body in Healthy Male Participants No drug interventions other 1 completed NCT05099172
First in Human Study of BAY2927088 in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations in the Genes of Epidermal Growth Factor Receptor (EGFR) and/or Human Epidermal Growth Factor Receptor 2 (HER2) No drug interventions treatment 1 / 2 recruiting NCT06329895
A Study to Learn About How BAY2927088 Affects the Level of Dabigatran or Rosuvastatin in the Blood When These Drugs Are Taken Together in Healthy Participants other 1 completed NCT01951469
Gefitinib With or Without Chemotherapy in Brain Metastases From Non-small Cell Lung Cancer treatment 3 unknown_status NCT02226757
Paclitaxel-trastuzumab in EGFR-mutated NSCLC Patients treatment 2 unknown_status NCT06378658
A Study to Learn About How Food and Esomeprazole Affect the Level of BAY2927088 in the Blood When Taken Together in Healthy Participants other 1 completed NCT05465343
Efficacy and Safety of Furmonertinib in Patients With EGFR Mutations in Advanced NSCLC With Brain Metastases: A Single-center, Open-label, Phase II Trial（iFORCE） No drug interventions treatment 2 unknown_status NCT05394233
Tislelizumab +Bevacizumab+pc for Untreated EGFR+ and High PD-L1 Non-squamous NSCLC treatment 2 unknown_status NCT04882345
Almonertinib Treats Advanced NSCLC Patients With EGFR Mutations Who Are Safety Intolerant After Osimertinib Treatment treatment 2 unknown_status NCT03071705
Metformin Plus TKI Use in Patients With Non-Small Cell Lung Carcinoma other Not Available unknown_status NCT05517083
Feasibility of Intratumoral Washing Fluid for Detecting EGFR Mutations in Lung Cancer No drug interventions diagnostic Not Available recruiting NCT02338011
Comparator-Controlled Study for EGFR(+) Patients With Multiple BMs From NSCLC (BROKE) (EGFR-epidermal Growth Factor Receptor;BM-brain Metastases) treatment 2 / 3 unknown_status NCT06018688
Osimertinib Combined With Aspirin Neoadjuvant Therapy for Resectable EGFR Mutated NSCLC Patients. treatment 2 not_yet_recruiting NCT04908956
Osimertinib and Locally Ablative Radiotherapy in Patients With Synchronous Oligo-metastatic EGFR Mutant NSCLC (STEREO) treatment 2 terminated NCT04201756
Neoadjuvant Afatinib Therapy for Potentially Resectable Stage III EGFR Mutation-Positive Lung Adenocarcinoma treatment 2 completed NCT03396185
Icotinib as Consolidation Therapy After Chemoradiotherapy in EGFR-Mutant Stage IIIA-IIIB Non-small Cell Lung Cancer treatment 2 unknown_status NCT03732352
18F-FDG PET and Osimertinib in Evaluating Glucose Utilization in Patients With EGFR Activated Recurrent Glioblastoma treatment 2 active_not_recruiting NCT04640870
The Molecular Epidemiology of Epidermal Growth Factor Receptor (EGFR) Mutations in Patients With Advanced EGFR Mutation-positive Non-small Cell Lung Cancer Treated With Afatinib Not Available Not Available completed NCT03171636
Frequency of EGFR and KRAS Mutations and Clinical-prognostic Correlation in Brazilian Lung Cancer Patients No drug interventions Not Available Not Available completed NCT06071013
Nintedanib Plus EGFR TKI In EGFR-mutated Non-small Cell Lung Cancer Patients treatment 1 / 2 not_yet_recruiting NCT03049618
Recombinant EphB4-HSA Fusion Protein and Pembrolizumab, MK-3475 treatment 2 active_not_recruiting NCT06300424
Neoadjuvant Almonertinib Followed by Chemo-immunotherapy in II-IIIB EGFR-mutant NSCLC treatment 2 recruiting NCT05314296
Osimertinib for Russian EGFR T790M Mutation-positive NSCLC Patients Who Progressed on or After EGFR TKI Therapy No drug interventions Not Available Not Available unknown_status NCT04042558
A Study Evaluating Platinum-Pemetrexed-Atezolizumab (+/-Bevacizumab) for Patients With Stage IIIB/IV Non-squamous Non-small Cell Lung Cancer With EGFR Mutations, ALK Rearrangement or ROS1 Fusion Progressing After Targeted Therapies treatment 2 recruiting NCT02947386
Nimotuzumab and Nivolumab in Treating Patients With Advanced Non-small Cell Lung Cancer treatment 1 completed NCT04695925
Phase III Study Comparing Osimertinib Monotherapy to Combination Therapy With Osimertinib,Carboplatin and Pemetrexed for Untreated Patients With Advanced Non-squamous Non-Small Cell Lung Cancer With Concurrent EGFR and TP53 Mutations treatment 3 unknown_status NCT04862780
(SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLC treatment 1 / 2 active_not_recruiting NCT06222489
Whole Body HER3 Quantification With Radiolabelled Patritumab Deruxtecan (HER3-DXd) PET/CT No drug interventions diagnostic 2 not_yet_recruiting NCT03046992
Clinical Trial of YH25448 in Patients With EGFR Mutation Positive Advanced NSCLC treatment 1 / 2 unknown_status NCT03002844
EGFR-TKI With/Without Chemotherapy in NSCLC Patients With Both EGFR Mutation and BIM Deletion Polymorphism treatment 2 unknown_status NCT06186401
Anti-EGFRvIII synNotch Receptor Induced Anti-EphA2/IL-13Ralpha2 CAR (E-SYNC) T Cells treatment 1 recruiting NCT04206072
D-0316 Versus Icotinib in Patients With Locally Advanced or Metastatic EGFR Sensitising Mutation Positive NSCLC treatment 2 / 3 active_not_recruiting NCT05370469
Real-Time Monitoring of Symptoms in Lung Cancer Patients Receiving Oral Targeted Therapies No drug interventions supportive_care Not Available active_not_recruiting NCT03042221
Early Rebiopsy to Identify Biomarkers of Tumor Cell Survival Following EGFR, ALK, ROS1 or BRAF TKI Therapy No drug interventions Not Available Not Available recruiting NCT03065387
Neratinib and Everolimus, Palbociclib, or Trametinib in Treating Participants With Refractory and Advanced or Metastatic Solid Tumors With EGFR Mutation/Amplification, HER2 Mutation/Amplification, or HER3/4 Mutation or KRAS Mutation treatment 1 active_not_recruiting NCT02098954
Erlotinib Combined With Chemotherapy in TKI Resistant Non-Small Cell Lung Cancers treatment 2 recruiting NCT05598528
Exploring the Mechanism of Primary Resistance to Third-generation EGFR-TKIs as First-line Treatment in EGFR-positive Advanced NSCLC (PRECISE Study) No drug interventions Not Available Not Available recruiting NCT06291688
Applying Mobile Healthcare Education to Improve Cutaneous Self-care Capability No drug interventions other Not Available recruiting NCT04085315
Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung Cancer treatment 1 recruiting NCT04013542
Ipilimumab and Nivolumab in Combination With Radiation Therapy in Treating Patients With Stage 2-3 Non-small Lung Cancer treatment 1 active_not_recruiting NCT04552613
Efficacy of Targeted Therapy Combined Chemotherapy in Advanced EGFR Positive NSCLC Patients treatment Not Available completed NCT06095934
Efficacy and Safety of Neoantigen Peptide Vaccine in the Treatment of Advanced NSCLC Progressed After EGFR-TKI Treatment No drug interventions treatment Not Available recruiting NCT03909334
Study of Osimertinib With and Without Ramucirumab in Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) treatment 2 active_not_recruiting NCT06521034
First-in-Human Phase I/II Study of FHND-9041 in Patients With EGFR Mutated Advanced Non-Small Cell Lung Cancer No drug interventions treatment 1 / 2 completed NCT03175224
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors treatment 2 recruiting NCT04512430
Neo-DIANA: Neoadjuvant Treatment for EGFR Mutated Patients treatment 2 terminated NCT06323148
Adjuvant Target Therapy Guided by ctDNA-MRD in Patients With EGFR-mutant II-IIIA Non-small Cell Lung Cancer (ECTOP-1022) treatment 3 not_yet_recruiting NCT04592666
Almonertinib/Pemetrexed/Carboplatin in EGFR T790M+ Advanced Lung Cancer treatment 2 unknown_status NCT06238882
Nitroglycerin Plus Radiotherapy Versus Conventional Radiotherapy in Patients With Lung Cancer. treatment Not Available recruiting NCT03720873
EGFR-TKIs Combine With Anlotinib as First-line Treatment for Patients With Advanced EGFR Mutation-positive NSCLC treatment 2 unknown_status NCT05033691
A Study to Evaluate the Efficacy of Osimertinib With Early Intervention SRS Treatment Compared to the Continuation of Osimertinib Alone, in Patients With EGFR Mutated NSCLC and Asymptomatic Brain Metastases No drug interventions treatment Not Available recruiting NCT04358562
Gefitinib With Anlotinib in Advanced Non-squamous NSCLC Patients With Uncleared Plasma ctDNA EGFRm After First-line Treatment With Gefitinib treatment 2 unknown_status NCT06436144
Osimertinib and Etoposide as First-Line Treatment in Osimertinib-Resistant Advanced EGFR-Mutant NSCLC treatment 2 not_yet_recruiting NCT06117644
The Efficacy of Double-dose Furmonertinib in the Treatment of Patients With Slow Osimertinib-resistant NSCLC No drug interventions Not Available Not Available not_yet_recruiting NCT05503667
Neoadjuvant Furmonertinib Plus Bevacizumab or Furmonertinib Monotherapy for Resectable and Potentially Resectable Stage III-IVA EGFR Mutation-Positive Lung Adenocarcinoma treatment 2 recruiting NCT03653546
First Line Treatment in EGFR Mutation Positive Advanced NSCLC Patients With Central Nervous System (CNS) Metastases treatment 2 / 3 completed NCT02886195
EGFR-TKIs Combine Chemotherapy as First-line Therapy for Patients With Advanced EGFR Mutation-positive NSCLC treatment 3 unknown_status NCT02954523
Dasatinib and Osimertinib (AZD9291) in Advanced Non-Small Cell Lung Cancer With EGFR Mutations treatment 1 / 2 terminated NCT02629523
Afatinib in Lung Cancer With EGFR Mutation From Circulating Tumor DNA treatment 2 completed NCT05153408
(HARMONY) Study of BLU-701 in EGFR-mutant NSCLC treatment 1 terminated NCT04322890
Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation treatment 2 recruiting NCT05698264
A Pilot Study to Understand the Impact of Therapy With Tumour Treating Fields (TTFields) in NSCLC No drug interventions treatment Not Available not_yet_recruiting NCT03755102
A Pilot Study of Dacomitinib With or Without Osimertinib for Patients With Metastatic EGFR Mutant Lung Cancers With Disease Progression on Osimertinib. treatment 0 completed NCT02769286
Osimertinib in First and Second Line Treatment of NSCLC Harboring EGFR Mutations From Circulating Tumor DNA treatment 2 completed NCT01074177
Understanding Mechanisms of Acquired Resistance to BIBW2992 treatment Not Available completed